Form D · Biotechnology
BioAge Labs, Inc.
Richmond, CA · CIK 0001709941
Offering snapshot reported Feb 13, 2024 · SEC filing
- Reported sold
- $194M Offering amount: $194M
- Investors reported
- 32 Form D · investor count
- Minimum accepted
- $3 Reported outside-investor minimum
- First sale
- Feb 1, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 13, 2024 | Initial | $194,390,799 | No comparison | 32 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-505095
Total offering includes $24,390,849 of Notes converting into Preferred Stock.
Source: Form D, filed Feb 13, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jason Coloma | Director |
| Patrick Enright | Director |
| Kristen Fortney | Director, Executive |
| Dov Goldstein | Executive |
| James Healy | Director |
| Rehka Hemrajani | Director |
| Eric Morgen | Director |
| Vijay Pande | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1445 A South 50 Th Street
Richmond, CA, 94804
Richmond, CA, 94804